The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA clears Investigational New Drug Application for phase I trial of ARQ 531 in patients with refractory B-cell malignancies

Apr 13, 2017

On 11 thApril 2017, the U.S. Food and Drug Administration ( FDA) has cleared an Investigational New Drug ( IND) application by ArQule Inc. to conduct a phase Ia/b trial of ARQ 531 in patients with refractory B-cell malignancies.

ARQ 531 is a potent, orally bioavailable, and reversible inhibitor of wild type and C481S-mutant Bruton’s Tyrosine Kinase (BTK).

CLL, DLBCL, MCL, and WM are driven by BTK. Currently, ibrutinibis the only approved BTK inhibitor; it is irreversible and makes a covalent bond with the C481 residue of the BTK protein. Clinical resistance to ibrutinib has been reported, and it seems that the predominant mechanism of resistance is the BTK C481S mutation. ARQ 531, being a reversible inhibitor, does not interact with the C481 residue and so is an attractive treatment option for patients with C481S-mutant BTK and resistant to irreversible BTK inhibitors.

The phase Ia/b trial is planned to start in Q3 of 2017. The Ia portion of the trial will be a dose escalation study aiming to define a recommended dose in patients with B-cell malignancies. Following this, the phase Ib trial will contain numerous expansion cohorts, including refractory patients harboring the C481S mutation.

  1. ResearchPool. ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531. 2017 Apr 11. [Accessed 2017 Apr 13].